Explore the Agenda
7:00 am Morning Registration & Breakfast
7:45 am Ice Breaker
Break the ice before the science begins. Join your table for a light hearted, TRP-themed networking activity designed to get conversations flowing, strengthen connections and maximise your networking opportunities throughout the summit.
7:55 am Chair’s Opening Remarks
Winning Global Regulatory Alignment to De Risk, Accelerate & Commercialise TRPs Worldwide
8:00 am I am the Person at the End of Your Pipeline: A Patient Perspective on the Future of Radiopharma
- My neuroendocrine cancer and theranostics journey: what early radioligand therapy has made possible
- A passion for connecting with stakeholders – every job in theranostics contributes to the wellbeing of patients like me
- Beyond access: helping patients understand, trust, and embrace radiopharmaceutical innovation
8:20 am Navigating Regulatory CMC Challenges Across Kit-Based & Ready-to-Use Radiopharmaceuticals: An Industry Perspective
- Comparing the distinct regulatory CMC considerations for kit-based and ready-to-use radiopharmaceuticals, spanning diagnostic and therapeutic applications and small to large vector approaches
- Examining key challenges, opportunities and areas of ambiguity within the evolving radiopharmaceutical regulatory framework, highlighting where further clarity could enable more effective development strategies
- Exploring industry perspectives on current regulatory expectations through practical, publicly available examples, identifying how different product formats are navigating CMC requirements in practice
- Opening the discussion to explore the challenges raised during the presentations, enabling audience-led discussion and exchange on evolving regulatory CMC expectations
Including an interactive regulatory panel and audience Q&A.
9:00 am Regulatory Leaders Fireside Chat: Regulatory Perspectives on the Future of Radiopharmaceutical Development: Where Can Greater International Alignment Enable Faster, More Predictable TRP Development
- Examining how regulatory agencies are adapting to the increasing complexity and pace of radiopharmaceutical innovation
- Understanding the unique quality, manufacturing and safety considerations associated with radiopharmaceutical products compared with conventional medicines
- Exploring where earlier dialogue between developers and regulators can help de-risk development and streamline regulatory interactions
- Sharing perspectives on the priorities required to support future innovation while maintaining robust standards for patient safety and product quality
10:00 am Speed Networking – How it Works
10:05 am Speed Networking
A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximise your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the Summit.
10:45 am Morning Break & Networking
Discovery & Preclinical Track
Discovery & Preclinical
Beyond Isotope Access: Aligning Radionuclide Selection with Clinical Applicability, Supply Reality & Commercial Feasibility
11:00 am Designing the Optimal Radiopharmaceutical: Matching Target, Ligand Design, Radionuclide and Disease Biology
Chief Scientific Officer, RadAlliance Therapeutics Inc
- Exploring how target biology, ligand properties, radionuclide characteristics and disease context work together to shape radiopharmaceutical performance.
- Examining how molecular design and pharmacokinetics drive biodistribution, tumor retention, normal-organ exposure and ultimately therapeutic index.
- Sharing lessons from next-generation radiopharmaceutical programs on integrating these factors to design differentiated therapies with improved clinical potential.
11:30 am Theranostics in Practice: Building the Foundations for Successful Radiopharmaceutical Development
- Establishing integrated theranostics programmes that support translational research and clinical delivery
- Aligning imaging, clinical and operational expertise to accelerate radiopharmaceutical development
- Creating collaborative ecosystems that enable innovation from bench to bedside
11:45 am Roundtable Discussion: Is Actinium-225 Ready for Mainstream Clinical Adoption? Balancing Scientific Promise with Development Reality
Chief Technology Officer, Nuclide Therapeutics
- Evaluating where Actinium-225 offers meaningful clinical advantages over established beta-emitting radionuclides to maximise patient benefit
- Overcoming isotope supply, manufacturing and infrastructure constraints to enable sustainable clinical development and future commercialisation
- Optimising target selection, dosimetry and therapeutic index to improve efficacy while minimising off-target toxicity
Translational & Clinical Track
Supply Chain & CMC
12:30 pm Lunch Break
Discovery & Preclinical Track
Building Next-Generation Preclinical Models to Better Predict Toxicity, Clinical Translation & First-in-Human Readiness
1:30 pm Re-Engineering the Therapeutic Window: Can Pre-Targeting Overcome the Fundamental Limitations of Conventional Radiopharmaceuticals?
Vice President CMC & Project Lead, OncoOne
- Examining how the pharmacokinetic coupling of tumor targeting and radionuclide delivery constrains the therapeutic window of conventional radiopharmaceuticals
- Exploring how pre-targeting separates tumor localization from radionuclide administration to improve tumor-to-non-tumor tissue exposure and enable more flexible radionuclide delivery
- Sharing lessons learned from candidate selection, platform optimization, and preclinical development in advancing next-generation pre-targeting technologies
- Identifying the target characteristics and disease settings most likely to benefit from pre-targeting and unlock previously inaccessible therapeutic opportunities
2:00 pm Session Reserved for Navigo Proteins
2:15 pm Roundtable Discussion: Beyond Regulatory Requirements: Maximising the Value of Toxicology Studies to De-Risk Preclinical Development
- Understanding the critical role of toxicology studies in supporting safe and successful radiopharmaceutical development
- Exploring how developers can generate additional translational insights from toxicology programmes beyond minimum regulatory requirements
- Examining the unique considerations associated with designing and interpreting toxicology studies for radiopharmaceuticals
Translational & Clinical Track
Supply Chain & CMC
3:00 pm Afternoon Break & Poster Session
Take this opportunity to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships whilst exploring the latest in radioligand therapy development and research advancements within poster presentations
From Late Line Success to Earlier Line Use: Redefining Radiopharmaceuticals as Transformative Frontline Cancer Therapies to Maximise Long-Term Patient Benefit & Disease Control
4:00 pm Integrating Radiopharmaceuticals into Standard of Care: Navigating Governance, Funding, Capacity, and Real-World Constraints
- Identifying the key barriers to integrating radiopharmaceuticals into standard care, including governance, funding models, regulatory frameworks, and system complexity
- Exploring how healthcare systems, industry, and regulators can collaborate to enable coordinated, scalable integration within existing constraints
- Assessing the infrastructure, workforce, and operational capacity required to support demand, including planning for variability between projected and real-world volumes
4:30 pm Building an Isotope Refinery: A New Class of Accelerator for the Theranostic Era
- The isotope supply challenge: the widening gap between clinical demand and what reactors, neutron sources and accelerators can produce today, and where that pressure is most acute for targeted radionuclide therapy
- The StandardX isotope production platform: how our FFA-type accelerator makes an isotope refinery possible, and what sets it apart as a new class of accelerator
- Progress so far and route to supply: milestones achieved to date, and the path ahead to commercial medical isotope supply
5:00 pm The Radioligand Flywheel From Multiparameter Optimization to Clinical Momentum
- AI navigates the multiparameter design space to identify promising radioligand profiles.
- Laboratory feedback improves every successive design cycle.
- Clinical insights connect patient-level evidence with the next generation of molecular designs.
5:30 pm Panel Discussion: Why Are Big Pharma Betting on Targeted Radiopharmaceuticals?
- Exploring the scientific, clinical and commercial factors driving increasing investment into targeted radiopharmaceuticals from large pharmaceutical companies
- Comparing the evolution of the radiopharmaceutical landscape with the rapid growth of antibody-drug conjugates and identifying the key lessons that can be applied across modalities
- Debating whether radiopharmaceuticals are approaching a similar inflection point to ADCs and what challenges still need to be overcome to unlock broader adoption
6:00 pm Investor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality?
- Identifying the scientific, clinical and commercial characteristics investors believe will differentiate tomorrow’s category leaders from an increasingly crowded pipeline
- Exploring which risks remain most significant to investment decisions, from manufacturing scalability and reimbursement to target differentiation and regulatory execution
- Evaluating the milestones that create the greatest enterprise value and discussing where capital should be deployed to maximise long-term commercial success